Erlichman et al (2001) showed that MDA-MB-231 cells transfected with BCRP had 4.9-fold lower accumulation of canertinib than cells transfected with empty vector, suggesting that canertinib is a substrate for BCRP. In both BCRP-transfected cells and unselected HCT8 colorectal carcinoma and T98G glioblastoma cells with endogenous BCRP expression, canertinib sensitised cells to SN-38 and topotecan. Consistently, canertinib increased the cellular accumulation of these drugs (Erlichman et al, 2001). Here, ABCG2 is linked to colorectal carcinoma.